Hyperfine, Inc. is an innovative health technology business focused on revolutionizing patient care through AI powered portable ultra low field magnetic resonance brain imaging. The company’s flagship product is the Swoop® system which creates diagnostic quality brain images at a fraction of the magnetic field strength used by conventional MRI scanners. Designed for use at the point of care the Swoop® system can be moved easily within hospitals clinics and physician…
Hyperfine, Inc. is an innovative health technology business focused on revolutionizing patient care through AI powered portable ultra low field magnetic resonance brain imaging. The company’s flagship product is the Swoop® system which creates diagnostic quality brain images at a fraction of the magnetic field strength used by conventional MRI scanners. Designed for use at the point of care the Swoop® system can be moved easily within hospitals clinics and physician offices without requiring specialized rooms or cryogenic cooling. The technology integrates an easy to use tablet based interface and proprietary AI software that enhances image quality while reducing scan time. By providing bedside imaging the Swoop® system aims to increase access to neuroimaging for patients in critical care emergency departments and outpatient neurology settings. Hyperfine, Inc. was founded in 2014 and has expanded its regulatory clearances and patent portfolio to support global commercialization.
Hyperfine, Inc. generates revenue primarily through the sale of the Swoop® system accompanied by an annual software service and support agreement. Under this model customers purchase the hardware and then enter into a multi year contract that provides software updates technical assistance and access to a cloud based picture archiving and communication system. The agreements are typically offered in thirty six month or sixty month terms with options for upfront payment of the device followed by annual service fees or a fully bundled annual payment. In some cases the system is sold without a service agreement though the majority of placements include the recurring support component. The company also earns income from the sale of accessories and from fees related to training and implementation services. Recurring revenue from service contracts is expected to improve gross margin as the installed base grows and as pricing is adjusted annually.
Hyperfine, Inc. occupies a distinctive niche within the broader magnetic resonance imaging market by offering the first FDA cleared AI powered portable ultra low field brain scanner. While major competitors such as General Electric Siemens Philips and Hitachi dominate the high field MRI landscape Hyperfine, Inc. focuses on underserved settings where conventional scanners are impractical due to cost size or infrastructure requirements. The company’s competitive advantages include its proprietary magnet design its noise cancellation technology and its deep learning powered image reconstruction which together deliver usable images at low field strength. A substantial patent estate with nearly two hundred issued patents and many pending applications further protects its technology. By positioning its product as a complement rather than a replacement for traditional MRI the firm seeks to augment existing capacity and improve workflow efficiency in intensive care units emergency departments and neurology offices.
The company serves hospitals health systems office based neurology practices and international healthcare providers. In the United States its initial focus has been on critical care units emergency departments and hospital based clinics where the Swoop® system enables bedside neuroimaging without patient transport. More recently Hyperfine, Inc. has expanded into the outpatient neurology office market allowing physicians to perform magnetic resonance examinations during routine visits. Outside the United States the firm relies on a network of distributors to sell and support the Swoop® system in countries such as Canada the United Kingdom Australia New Zealand India and various European and Middle Eastern markets. Specific customer names are not disclosed in the filing but the target audience includes acute care facilities academic medical centers community hospitals and private neurology clinics.
Sector:HealthcareSector rationaleHyperfine designs and manufactures the Swoop® system, which is a portable magnetic resonance brain imaging device sold to hospitals, clinics, and neurology practices. This falls squarely under the Medical Devices industry within the Healthcare sector, as the company's primary revenue comes from selling this diagnostic hardware and associated medical software services.Industry:Diagnostic EquipmentHealthcarePrimaryHyperfine manufactures and sells the Swoop® system, which is a portable ultra low field magnetic resonance brain imaging scanner used for clinical diagnosis. The company generates revenue from the sale of these diagnostic instruments and recurring software service and support agreements.Classified using BQ-MICSCIK: 0001833769
Investment Thesis
▲ Bull case
The company's second-generation Swoop system with Optive AI software has demonstrated strong clinical utility, with the NEURO-PMR study showing 92% concordance with conventional MRI in blinded reviews and 98% in unblinded reviews, positioning the technology as a credible alternative in neurology offices where only 10% of practices currently have on-site MRI, creating a vast addressable market with minimal competition and enabling point-of-care diagnostics that improve patient satisfaction and reduce system bottlenecks.
International expansion is accelerating with CE Mark and UKCA approvals for both the next-generation Swoop system and Optive AI software, allowing commercialization across Europe and the UK starting in Q3 2026, while the deployment at AIIMS New Delhi validates demand in high-need emerging markets where transport to conventional MRI is often impossible, establishing a foundation for broader adoption and clinical research generation in underserved regions.
Health economic evidence from Jefferson Abington showing 1- to 1.5-year ROI for Swoop systems—substantially better than the 3- to 4-year typical for capital equipment—is becoming a powerful catalyst for hospital decisions, accelerating deal conversations to C-suite level and justifying the $590,000 MSRP increase in the U.S. hospital segment without slowing deal momentum, as administrative ROI remains compelling even at the higher price point.
The PRIME study results demonstrating a median 6.35-hour reduction in time to imaging in emergency departments compared to conventional MRI address a critical pain point in ED workflows, where delays impact patient outcomes and boarding times, positioning Swoop as an efficient adjunct that can integrate rapidly into triage pathways and expand access to advanced neuroimaging where conventional MRI remains difficult to obtain.
The company's cash runway extending into 2028 following the October equity issuance and access to the $15 million initial tranche of its long-term debt facility (with up to $25 million additional available through 2027) provides significant financial flexibility to invest in commercialization, product development, and international expansion without near-term financing pressure, supporting sustained growth through 2026 and beyond.
The company's second-generation Swoop system with Optive AI software has demonstrated strong clinical utility, with the NEURO-PMR study showing 92% concordance with conventional MRI in blinded reviews and 98% in unblinded reviews, positioning the technology as a credible alternative in neurology offices where only 10% of practices currently have on-site MRI, creating a vast addressable market with minimal competition and enabling point-of-care diagnostics that improve patient satisfaction and reduce system bottlenecks.
International expansion is accelerating with CE Mark and UKCA approvals for both the next-generation Swoop system and Optive AI software, allowing commercialization across Europe and the UK starting in Q3 2026, while the deployment at AIIMS New Delhi validates demand in high-need emerging markets where transport to conventional MRI is often impossible, establishing a foundation for broader adoption and clinical research generation in underserved regions.
Health economic evidence from Jefferson Abington showing 1- to 1.5-year ROI for Swoop systems—substantially better than the 3- to 4-year typical for capital equipment—is becoming a powerful catalyst for hospital decisions, accelerating deal conversations to C-suite level and justifying the $590,000 MSRP increase in the U.S. hospital segment without slowing deal momentum, as administrative ROI remains compelling even at the higher price point.
The PRIME study results demonstrating a median 6.35-hour reduction in time to imaging in emergency departments compared to conventional MRI address a critical pain point in ED workflows, where delays impact patient outcomes and boarding times, positioning Swoop as an efficient adjunct that can integrate rapidly into triage pathways and expand access to advanced neuroimaging where conventional MRI remains difficult to obtain.
The company's cash runway extending into 2028 following the October equity issuance and access to the $15 million initial tranche of its long-term debt facility (with up to $25 million additional available through 2027) provides significant financial flexibility to invest in commercialization, product development, and international expansion without near-term financing pressure, supporting sustained growth through 2026 and beyond.
Revenue growth is heavily dependent on multi-unit hospital and IDN deals that are now more mainstream procurement processes tied to annual budget cycles, creating potential quarterly lumpiness and variability as larger deals progress slowly through administrative processes, which management acknowledged could cause revenue to strengthen progressively through the year rather than evenly, making consistent quarterly performance unpredictable.
Service revenue declined in Q1 2026 due to accounting adjustments from technology upgrades, and while management expects it to rise with the installed base, the current trend raises concerns about the scalability of recurring revenue streams, which are critical for long-term margin expansion and customer retention as the hardware business faces potential pricing pressure or saturation in early adopter segments.
The Contrast PMR study, intended to support FDA submission for gadolinium-based contrast use by late 2026, is only 20% enrolled, indicating slow progress that may delay regulatory expansion into contrast-enhanced imaging—a key unlock for broader neurological and surgical applications—and risks missing the anticipated timeline, limiting near-term revenue potential from advanced use cases.
International expansion, while advancing with CE/UKCA approvals, remains reliant on distributor networks where pricing produces blended ASPs, and the company has not disclosed specific commercialization timelines or expected adoption rates in Europe beyond initiating efforts in Q3 2026, leaving uncertainty about whether international sales will meaningfully contribute to 2026 revenue guidance given the historical lag between regulatory approval and meaningful sales uptake in new geographic markets.
Gross margin guidance of 50% to 55% for 2026 assumes continued expansion from the 49.8% full-year 2025 level, but this depends on sustaining second-half margin improvement amid potential mix shifts from international distributor sales (which may carry lower margins) and increased service revenue, while R&D spending, though reduced, remains elevated at $3.8 million quarterly and could pressure profitability if revenue growth fails to accelerate as projected.
Revenue growth is heavily dependent on multi-unit hospital and IDN deals that are now more mainstream procurement processes tied to annual budget cycles, creating potential quarterly lumpiness and variability as larger deals progress slowly through administrative processes, which management acknowledged could cause revenue to strengthen progressively through the year rather than evenly, making consistent quarterly performance unpredictable.
Service revenue declined in Q1 2026 due to accounting adjustments from technology upgrades, and while management expects it to rise with the installed base, the current trend raises concerns about the scalability of recurring revenue streams, which are critical for long-term margin expansion and customer retention as the hardware business faces potential pricing pressure or saturation in early adopter segments.
The Contrast PMR study, intended to support FDA submission for gadolinium-based contrast use by late 2026, is only 20% enrolled, indicating slow progress that may delay regulatory expansion into contrast-enhanced imaging—a key unlock for broader neurological and surgical applications—and risks missing the anticipated timeline, limiting near-term revenue potential from advanced use cases.
International expansion, while advancing with CE/UKCA approvals, remains reliant on distributor networks where pricing produces blended ASPs, and the company has not disclosed specific commercialization timelines or expected adoption rates in Europe beyond initiating efforts in Q3 2026, leaving uncertainty about whether international sales will meaningfully contribute to 2026 revenue guidance given the historical lag between regulatory approval and meaningful sales uptake in new geographic markets.
Gross margin guidance of 50% to 55% for 2026 assumes continued expansion from the 49.8% full-year 2025 level, but this depends on sustaining second-half margin improvement amid potential mix shifts from international distributor sales (which may carry lower margins) and increased service revenue, while R&D spending, though reduced, remains elevated at $3.8 million quarterly and could pressure profitability if revenue growth fails to accelerate as projected.